2017 American Transplant Congress
Presence of Anellovirus Nucleic Acid Sequences in Involved Tissue Is Associated with Worse Patient Survival in Post-Transplant Lymphoproliferative Disorder.
Washington University in St Louis School of Medicine, St. Louis
Introduction: PTLD remain a feared complication of organ and tissue transplant, with high morbidity and mortality. While 50-80% of cases are strongly associated with Epstein-Barr…2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…2017 American Transplant Congress
Risk of Primary Central Nervous System Lymphoma in Solid Organ Transplant Recipients.
National Cancer Institute, Bethesda, MD
Background: Risk of primary central nervous system lymphoma (PCNSL) is greatly increased in immunosuppressed HIV-infected people. Case series describe PCNSL in solid organ transplant (SOT)…2017 American Transplant Congress
Does EBV Viremia at Time of Transplant Have a Negative Impact on Transplant Outcomes?
University of Minnesota, Minneapolis
Being EBV antibody (Ab) positive at the time of transplant increases the risk of post-transplant lymphoproliferative disorder (PTLD) and is a significant threat to patient…2016 American Transplant Congress
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.
Medicine, University of Alberta, Edmonton, Canada.
Purpose: The presence of passive antibodies, transfusion-acquired or maternal in infants, can make serologic determination of pre-transplant CMV and EBV status in children unreliable. We…2016 American Transplant Congress
NKG2A-Expressing Natural Killer Cells Dominate the Response to Latent Epstein-Barr Virus Infection.
Introduction: EBV infection elicits a robust host immune response in healthy, immunocompetant individuals. EBV immunity is essential for preventing EBV-associated lymphomas in transplant recipients, including…2016 American Transplant Congress
Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
At 7 yrs post transplant in BENEFIT-EXT (NCT00114777), bela-treated pts had similar graft survival and improved renal function vs CsA-treated pts. Bela is indicated for…2016 American Transplant Congress
Identification of MicroRNAs in EBV+ B Cell Lymphomas and Secreted Exosomes.
Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford.
Introduction Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of organ transplantation commonly associated with Epstein Barr virus (EBV) infection. EBV viral loads are…2016 American Transplant Congress
Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel IS agent that acts through costimulatory blockade of T-cells and obviates the need for CNI. Despite benefits in improving renal…2016 American Transplant Congress
Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.
Stanford School of Medicine, Stanford, CA.
EBV is linked to a variety of lymphoid and epithelial malignancies. In transplant recipients EBV is associated with the development of B cell lymphomas in…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »